A 2-Year Prospective Randomized Controlled Trial of Intravitreal Bevacizumab or Laser Therapy (BOLT) in the Management of Diabetic Macular Edema
Top Cited Papers
- 1 August 2012
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 130 (8), 972-979
- https://doi.org/10.1001/archophthalmol.2012.393
Abstract
ObjectiveTo report the 2-year outcomes of the BOLT study, a prospective randomized controlled trial evaluating intravitreous bevacizumab and modified Early Treatment Diabetic Retinopathy Study (ETDRS) macular laser therapy (MLT) in patients with persistent clinically significant macular edema (CSME).MethodsIn a 2-year, single-center, randomized controlled trial, 80 patients with center-involving CSME and visual acuity of 20/40 to 20/320 were randomized to receive either bevacizumab or MLT.Main Outcome MeasuresPrimary outcome: difference in ETDRS best-corrected visual acuity (BCVA) between arms. Secondary outcomes: mean change in BCVA, proportion gaining at least 15 and at least 10 ETDRS letters, losing fewer than 15 and at least 30 letters, change in central macular thickness, ETDRS retinopathy severity, and safety outcomes.ResultsAt 2 years, mean (SD) ETDRS BCVA was 64.4 (13.3) (ETDRS equivalent Snellen fraction: 20/50) in the bevacizumab arm and 54.8 (12.6) (20/80) in the MLT arm (P = .005). The bevacizumab arm gained a median of 9 ETDRS letters vs 2.5 letters for MLT (P = .005), with a mean gain of 8.6 letters for bevacizumab vs a mean loss of 0.5 letters for MLT. Forty-nine percent of patients gained 10 or more letters (P = .001) and 32% gained at least 15 letters (P = .004) for bevacizumab vs 7% and 4% for MLT. Percentage who lost fewer than 15 letters in the MLT arm was 86% vs 100% for bevacizumab (P = .03). Mean reduction in central macular thickness was 146 μm in the bevacizumab arm vs 118 μm in the MLT arm. The median number of treatments over 24 months was 13 for bevacizumab and 4 for MLT.ConclusionsThis study provides evidence supporting longer-term use of intravitreous bevacizumab for persistent center-involving CSME.Application to Clinical PracticeImprovements in BCVA and central macular thickness seen with bevacizumab at 1 year were maintained over the second year with a mean of 4 injections.Trial Registrationeudract.ema.europa.eu Identifier: 2007-000847-89Keywords
This publication has 23 references indexed in Scilit:
- Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edemaClinical Ophthalmology, 2011
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)Diabetes Care, 2010
- Prevalence of Diabetic Retinopathy in the United States, 2005-2008JAMA, 2010
- The global burden of diabetes and its complications: an emerging pandemicEuropean Journal of Preventive Cardiology, 2010
- MACULAR PERFUSION DETERMINED BY FUNDUS FLUORESCEIN ANGIOGRAPHY AT THE 4-MONTH TIME POINT IN A PROSPECTIVE RANDOMIZED TRIAL OF INTRAVITREAL BEVACIZUMAB OR LASER THERAPY IN THE MANAGEMENT OF DIABETIC MACULAR EDEMA (BOLT STUDY)Retina, 2010
- Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular EdemaOphthalmology, 2010
- Pharmacokinetics of Bevacizumab and Its Effect on Vascular Endothelial Growth Factor after Intravitreal Injection of Bevacizumab in Macaque EyesInvestigative Opthalmology & Visual Science, 2010
- Effect of Prior Intensive Therapy in Type 1 Diabetes on 10-Year Progression of Retinopathy in the DCCT/EDIC: Comparison of Adults and AdolescentsDiabetes, 2010
- Randomized Trial of Intravitreal Bevacizumab Alone or Combined with Triamcinolone versus Macular Photocoagulation in Diabetic Macular EdemaOphthalmology, 2009